Innate Pharma Valuation
| IPHA Stock | USD 1.95 0.07 3.47% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Innate Pharma retains a regular Real Value of $3.28 per share. The prevalent price of the firm is $1.95. Our model calculates the value of Innate Pharma from evaluating the firm fundamentals such as Current Valuation of 109.8 M, return on asset of -0.14, and Return On Equity of -0.79 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Innate Pharma's valuation include:
Price Book 5.3864 | Enterprise Value | Enterprise Value Ebitda (6.94) | Price Sales 5.1214 | Enterprise Value Revenue 4.0483 |
Undervalued
Today
Please note that Innate Pharma's price fluctuation is very risky at this time. Calculation of the real value of Innate Pharma is based on 3 months time horizon. Increasing Innate Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Innate Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Innate Stock. However, Innate Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.95 | Real 3.28 | Target 7.41 | Hype 1.95 | Naive 1.94 |
The real value of Innate Stock, also known as its intrinsic value, is the underlying worth of Innate Pharma Company, which is reflected in its stock price. It is based on Innate Pharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Innate Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Innate Pharma helps investors to forecast how Innate stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Innate Pharma more accurately as focusing exclusively on Innate Pharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Innate Pharma's intrinsic value based on its ongoing forecasts of Innate Pharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Innate Pharma's closest peers. If more than one evaluation category is relevant for Innate Pharma we suggest using both methods to arrive at a better estimate.
Innate Pharma Cash |
|
Innate Valuation Trend
Comparing Innate Pharma's enterprise value against its market capitalization is a good way to estimate the value of Innate Pharma uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Innate Pharma Total Value Analysis
Innate Pharma is currently forecasted to have valuation of 109.8 M with market capitalization of 173.04 M, debt of 39.89 M, and cash on hands of 123.35 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Innate Pharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
109.8 M | 173.04 M | 39.89 M | 123.35 M |
Innate Pharma Investor Information
The company recorded a loss per share of 0.46. Innate Pharma had not issued any dividends in recent years. Based on the key measurements obtained from Innate Pharma's financial statements, Innate Pharma is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Innate Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Innate Pharma has an asset utilization ratio of 28.18 percent. This suggests that the Company is making $0.28 for each dollar of assets. An increasing asset utilization means that Innate Pharma is more efficient with each dollar of assets it utilizes for everyday operations.Innate Pharma Ownership Allocation
Innate Pharma has a total of 83.81 Million outstanding shares. Roughly 99.71 (percent) of Innate Pharma outstanding shares are held by general public with 0.29 pct. by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Innate Pharma Profitability Analysis
The company reported the previous year's revenue of 51.9 M. Net Loss for the year was (7.57 M) with loss before overhead, payroll, taxes, and interest of (19.86 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Innate Pharma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Innate Pharma and how it compares across the competition.
About Innate Pharma Valuation
The stock valuation mechanism determines Innate Pharma's current worth on a weekly basis. Our valuation model uses a comparative analysis of Innate Pharma. We calculate exposure to Innate Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Innate Pharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -4.7 M | -4.5 M | |
| Pretax Profit Margin | (0.13) | (0.14) | |
| Operating Profit Margin | (0.22) | (0.23) | |
| Net Loss | (0.13) | (0.14) | |
| Gross Profit Margin | (0.09) | (0.10) |
Innate Pharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 80.5 M | |
| Quarterly Earnings Growth Y O Y | -0.747 |
Innate Pharma Current Valuation Indicators
Valuation refers to the process of determining the present value of Innate Pharma and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Innate we look at many different elements of the entity such as Innate's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Innate Pharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Innate Pharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Innate Pharma's worth.Complementary Tools for Innate Stock analysis
When running Innate Pharma's price analysis, check to measure Innate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innate Pharma is operating at the current time. Most of Innate Pharma's value examination focuses on studying past and present price action to predict the probability of Innate Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innate Pharma's price. Additionally, you may evaluate how the addition of Innate Pharma to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |